This is very frustrating. I have the chance to travel quite a bit and meet with numerous medical partners —academic leaders, industrial experts, thought leaders and medical device executives. Many of them are as passionate as I am about using simulation to accelerate the pace of innovation for medical device and pharmaceutical solutions. Yet, most of them are amazed when I show them some of the achievements of their peers. Some simply didn’t know that this application or model was possible to simulate or didn’t know how to do it .If all of them would share great results in their areas of expertise then everyone could learn and benefit.
This is not acceptable for an industry where our pace of innovation means better comfort, less pain or perhaps survival for the patient! Continue reading
“Innovation in healthcare is not just a question of business; often it is a matter of life and death. Medical and pharmaceutical companies must turn a profit, but they also have an ethical duty to improve lives — addressing common chronic illnesses and providing effective treatments for rare conditions — no matter the lack of profitability. Healthcare companies, therefore, face the dilemma of how to minimize cost and maximize efficiency.” Continue reading
This year’s Super Bowl and an often controversial NFL season are behind us and I’d like to congratulate the New England Patriots on the nice win. (Seattle, you put up a good fight but that was a pretty risky call at the last minute!) But, even as the win by the Pats fades, a new controversy has stirred. Seahawks defensive end Cliff Avril exited the Super Bowl in the third quarter after being diagnosed with a concussion. Patriots wide receiver Julian Edelman passed a concussion test during the Super Bowl on Sunday, allowing him to continue to play, but it could have just as easily gone the other way. Continue reading
Last weekend, I attended the major wine fair in Lille, France. Bottles of St Emilion Grand Cru Classé, Chateauneuf du Pape, St Joseph, Saumur-Champigny found their way to my cellar in preparation for the sumptuous dinners I’m planning around Christmas. Young red wines are good for cardiovascular system, whereas, an excess of good wine and good food is not a good idea for a long and healthy life. Continue reading
A few weeks ago, I participated to the biomedical track of the ANSYS CADFEM Users Meeting (ACUM) in Nuremberg, Germany — an amazing meeting where many medical device companies, academic leaders, clinicians and surgeons shared their experiences and stressed the need to accelerate the adoption of engineering simulation for medical and clinical applications. Continue reading
Stacey Cook (USA) performing with the Rossignol skis
Wow, the 2014 Olympic Winter Games in Sochi have been amazing and make me even more impatient to go to skiing in early April. I’ll especially remember three of the sporting events. First, Bart Swings from Belgium finished in fourth place in the 5,000-meter speed skating just behind a fully Dutch podium. Maybe aerodynamic simulation could have improved his performance and delivered him a place on the platform. There was also some great ski jumping where the skiers literally flew, and I found a flapping ski to perfectly illustrate fluid–structure interaction. I don’t know if this flapping is good or bad for performance. What do you think? Finally, I’ll remember the breathtaking downhill race. Continue reading
Tomorrow, December 6, is an important day for many because it’s the final draw that will deliver the verdict on the eight football (soccer) groups that will kick off the 2014 FIFA World Cup — one of the most popular sporting events in the world, surpassed only by the Olympic Games. The 2014 World Cup will take place in Brazil from June 12 to July 1. This year will be special for me because, for the first time since 2002, Belgium has qualified. The team from Belgium includes a large number of players from prestigious European championships, so we have a fair chance to go quite far in the competition.
Whether the Belgian team will be a tough competitor or an easy seed could influence the rest of the World Cup. Unfortunately, it is very unlikely I will be able to support our Belgian Red Devils in person in Brazil next summer. But I’ll feel a part of the event thanks to the remarkable work done under the auspices of NOVACAP, Maruska Holanda and Pedro Almeida performed by Prof. Paulo de Mattos Pimenta and ESSS, the ANSYS channel partner in South America.
The Stadium That Will Host the 2014 World Cup
The National Stadium of Brasilia Mane Garrincha
Because a stadium is usually considered a prestigious landmark that is expected to last for decades, the quality of the design is crucial. The stadium must be able to withstand any situation it might experience during its lifetime such as heavy wind or cheering crowds. Continue reading
Two weeks ago, while visiting some partners of the ANGIOVISION project, I had the unique opportunity to be in the operating room to attend an open heart surgery. It was fascinating to see live what we have been simulating for years. The replacement of the calcified heart valve combined with some bypass is a delicate surgery that necessitates extra corporeal blood circulation. I found myself very aware of the anxiety felt by the patient’s family, as my father-in-law had a similar operation a few months ago.
Despite the complexity of the situation, I was amazed by the serenity of the surgeon moving from step-to-step with professionalism, expertise and extreme calm, taking a few seconds to show me in reality what I usually see on the screen. For sure, the most moving time was when they brought the heart back to working temperature and watching this robust pump spontaneously feeding life into the body again. Continue reading
A year ago we were all amazed by the daring achievements of so many athletes during the Olympics. We discussed the impact of engineering simulation for these elites in a special edition of our ANSYS Advantage magazine. Personally, I look forward to each summer in July, when I watch with great admiration as cycling athletes embark on the route of the Tour de France. Once again, I’m very proud that ANSYS is somewhat part of the race through our clients.
Like most others, I’m impressed by the mountain ascents, watching the leaders who climb these slopes at an amazing speed. But I also respect those behind the leaders, who reach the summits with the thought of assisting their teammates the day after. Geographic names like Alpes D’Huez, Galibier, Col de la Madeleine and, of course, the beast Mont Ventoux, the giant of Provence, all sound like exceptional challenges reserved for an elite pack. Continue reading
If I had to choose a winner for the Best ACTor in 2012, It would be Oticon A/S in Denmark, a world-leading developer of hearing aids. I’ll tell you more about that company later. But first, let’s talk about ACTing and ACTors. ACT is ANSYS’ Application Customization Toolkit. It can help to capture analysts’ expertise and know-how as well as give non-expert users access to advanced models, among other things. But why is this tool so important?
I keep hearing people say that “there are no better codes than our in-house codes, as they are perfectly fitted for a given application.” But the reality is: The cost of developing and maintaining in-house codes — not to mention issues related to an integrated environment (CAD integration, meshing, post-processing, optimization and DoE) — simply makes the practice unsustainable. Continue reading